Zacks Investment Research on MSN
FDA grants breakthrough therapy designation to ALKS' narcolepsy drug
Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...
Chip Chick on MSN
His wife left him for another guy, but wants him back now that he's dating an old friend of his
I always find it interesting when someone throws their spouse and marriage away, only to want it all back the minute their ...
An evidence-based web-app helped children with epilepsy to fall asleep on average 16.5 minutes earlier. A new UK-wide ...
New data reveals AL ranks near the top for sleep deprivation, with close to half of adults reporting they don’t get enough ...
Alixorexton is an oral selective orexin 2 receptor agonist expected to reduce excessive daytime sleepiness across hypersomnolence disorders such as narcolepsy.
Sleep hygiene refers to habits that support good-quality sleep. These include allowing enough time for sleep, keeping your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback